Trial Profile
Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Afimoxifene (Primary) ; Tamoxifen
- Indications Breast cancer; Ductal carcinoma
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 20 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 02 May 2013 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
- 31 Jan 2012 Planned end date changed from 1 Feb 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov.